HEADER ANTIBIOTIC/PEPTIDE 29-DEC-00 1HHZ TITLE DEGLUCOBALHIMYCIN IN COMPLEX WITH CELL WALL PENTAPEPTIDE CAVEAT 1HHZ DAL E 1 HAS WRONG CHIRALITY AT ATOM CA DAL E 1 C-ALPHA WRONG CAVEAT 2 1HHZ HAND DAL E 1 C-ALPHA WRONG HAND COMPND MOL_ID: 1; COMPND 2 MOLECULE: DEGLUCOBALHIMYCIN; COMPND 3 CHAIN: A, B, C; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: CELL WALL PEPTIDE; COMPND 7 CHAIN: D, E, F; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: AMYCOLATOPSIS SP.; SOURCE 4 ORGANISM_TAXID: 37632; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES; SOURCE 7 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 8 ORGANISM_TAXID: 32630 KEYWDS ANTIBIOTIC-PEPTIDE COMPLEX, GLYCOPEPTIDE, ANTIBIOTIC, CELL WALL KEYWDS 2 PEPTIDE, BALHIMYCIN EXPDTA X-RAY DIFFRACTION AUTHOR C.LEHMANN,G.BUNKOCZI,G.M.SHELDRICK,L.VERTESY REVDAT 8 29-JUL-20 1HHZ 1 CAVEAT REMARK LINK SITE REVDAT 7 09-OCT-19 1HHZ 1 SOURCE REVDAT 6 24-JUL-19 1HHZ 1 REMARK REVDAT 5 10-JUL-19 1HHZ 1 REMARK REVDAT 4 24-APR-19 1HHZ 1 REMARK SEQRES LINK REVDAT 3 13-JUL-11 1HHZ 1 VERSN REVDAT 2 24-FEB-09 1HHZ 1 VERSN REVDAT 1 05-SEP-03 1HHZ 0 JRNL AUTH C.LEHMANN,G.BUNKOCZI,L.VERTESY,G.M.SHELDRICK JRNL TITL STRUCTURES OF GLYCOPEPTIDE ANTIBIOTICS WITH PEPTIDES THAT JRNL TITL 2 MODEL BACTERIAL CELL-WALL PRECURSORS JRNL REF J.MOL.BIOL. V. 318 723 2002 JRNL REFN ISSN 0022-2836 JRNL PMID 12054818 JRNL DOI 10.1016/S0022-2836(02)00146-8 REMARK 2 REMARK 2 RESOLUTION. 0.99 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.99 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 41.85 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : SHELLS REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.108 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.108 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.140 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1529 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 29932 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.103 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.102 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.135 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1413 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 27252 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 320 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 53 REMARK 3 SOLVENT ATOMS : 95 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 448.50 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 280.80 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 6 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 4237 REMARK 3 NUMBER OF RESTRAINTS : 4905 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.021 REMARK 3 ANGLE DISTANCES (A) : 0.032 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.027 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.086 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.084 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.190 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.085 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.005 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.027 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.126 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: METHOD USED: MOEWS & KRETSINGER, REMARK 3 J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1HHZ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 29-DEC-00. REMARK 100 THE DEPOSITION ID IS D_1290005734. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-MAR-99 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : EMBL/DESY, HAMBURG REMARK 200 BEAMLINE : X11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9114 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29932 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.990 REMARK 200 RESOLUTION RANGE LOW (A) : 41.850 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 7.500 REMARK 200 R MERGE (I) : 0.05300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.99 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.10 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 7.50 REMARK 200 R MERGE FOR SHELL (I) : 0.19000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: DIRECT METHODS REMARK 200 SOFTWARE USED: SHELX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.10 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.3M CIT, PH=7, 30% 1,2-PROPANEDIOL, REMARK 280 PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 26.20000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 13.10000 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 13.10000 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 26.20000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1390 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 3270 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -6.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, C, E, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2240 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2280 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -15.8 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 52.40000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A2006 LIES ON A SPECIAL POSITION. REMARK 375 HOH F2001 LIES ON A SPECIAL POSITION. REMARK 400 REMARK 400 COMPOUND REMARK 400 BALHIMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY TWO MONOSACCHARIDES: A D-GLUCOSE REMARK 400 AND A 4-OXO-VANCOSAMINE. REMARK 400 HERE, DEGLUCOBALHIMYCIN IS REPRESENTED GROUPING TOGETHER THE REMARK 400 SEQUENCE (SEQRES) AND ONE LIGAND (HET) DVC. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: DEGLUCOBALHIMYCIN REMARK 400 CHAIN: A, B, C REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 7 REMARK 400 COMPONENT_2: SUGAR RESIDUES 9 REMARK 400 DESCRIPTION: DEGLUCOBALHIMYCIN LACKS THE D-GLUCOSE REMARK 400 COMPONENT OF BALHIMYCIN CONSISTING OF THE REMARK 400 TRICYCLIC HEPTAPEPTIDE AND 4-OXO-VANCOSAMINE REMARK 400 ONLY, LINKED TO RESIDUE 6. REMARK 400 REMARK 400 THE DEGLUCOBALHIMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC, REMARK 400 ANTIMICROBIAL CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: DEGLUCOBALHIMYCIN REMARK 400 CHAIN: A, B, C REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE DVC REMARK 400 DESCRIPTION: DEGLUCOBALHIMYCIN LACKS THE D-GLUCOSE COMPONENT OF REMARK 400 BALHIMYCIN CONSISTING OF THE TRICYCLIC HEPTAPEPTIDE REMARK 400 AND (2R,4S,6S)-4-AZANYL-4,6-DIMETHYL-OXANE-2,5,5- REMARK 400 TRIOL ONLY LINKED TO RESIDUE 6. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 DAL D 1 REMARK 465 DAL F 1 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 FGA D 2 N CA C O CB REMARK 470 LYS D 3 CD CE NZ REMARK 470 FGA F 2 C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 3 -56.01 -120.78 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH B2004 DISTANCE = 6.01 ANGSTROMS REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1GO6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BALHIMYCIN COMPLEXED WITH THE PEPTIDE LYS-DAL- REMARK 900 DAL REMARK 900 RELATED ID: 1HHY RELATED DB: PDB REMARK 900 CRYSTAL STRUCURE OF DEGLUCOBALHIMYCIN COMPLEXED WITH DAL-DAL REMARK 900 RELATED ID: 1HHU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BALHIMYCIN COMPLEXED WITH DAL-DAL DBREF 1HHZ A 1 7 NOR NOR00707 NOR00707 1 7 DBREF 1HHZ B 1 7 NOR NOR00707 NOR00707 1 7 DBREF 1HHZ C 1 7 NOR NOR00707 NOR00707 1 7 DBREF 1HHZ D 1 5 PDB 1HHZ 1HHZ 1 5 DBREF 1HHZ E 1 5 PDB 1HHZ 1HHZ 1 5 DBREF 1HHZ F 1 5 PDB 1HHZ 1HHZ 1 5 SEQRES 1 A 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 B 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 C 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 D 5 DAL FGA LYS DAL DAL SEQRES 1 E 5 DAL FGA LYS DAL DAL SEQRES 1 F 5 DAL FGA LYS DAL DAL MODRES 1HHZ OMY A 6 TYR MODRES 1HHZ OMY B 6 TYR MODRES 1HHZ OMY C 6 TYR HET MLU A 1 9 HET OMZ A 2 14 HET GHP A 4 11 HET GHP A 5 11 HET OMY A 6 14 HET 3FG A 7 13 HET MLU B 1 9 HET OMZ B 2 14 HET GHP B 4 11 HET GHP B 5 11 HET OMY B 6 14 HET 3FG B 7 13 HET MLU C 1 9 HET OMZ C 2 14 HET GHP C 4 11 HET GHP C 5 11 HET OMY C 6 14 HET 3FG C 7 13 HET FGA D 2 3 HET DAL D 4 5 HET DAL D 5 6 HET DAL E 1 10 HET FGA E 2 9 HET DAL E 4 5 HET DAL E 5 6 HET FGA F 2 6 HET DAL F 4 5 HET DAL F 5 6 HET DVC A 9 11 HET PGR A1001 5 HET PGR A1002 5 HET DVC B 9 11 HET PGR B1001 5 HET DVC C 9 11 HET PGR C1001 5 HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM FGA GAMMA-D-GLUTAMIC ACID HETNAM DAL D-ALANINE HETNAM DVC (2R,4S,6S)-4-AZANYL-4,6-DIMETHYL-OXANE-2,5,5-TRIOL HETNAM PGR R-1,2-PROPANEDIOL HETSYN FGA D-GLUTAMIC ACID FORMUL 1 MLU 3(C7 H15 N O2) FORMUL 1 OMZ 3(C9 H10 CL N O4) FORMUL 1 GHP 6(C8 H9 N O3) FORMUL 1 OMY 3(C9 H10 CL N O4) FORMUL 1 3FG 3(C8 H9 N O4) FORMUL 4 FGA 3(C5 H9 N O4) FORMUL 4 DAL 7(C3 H7 N O2) FORMUL 7 DVC 3(C7 H15 N O4) FORMUL 8 PGR 4(C3 H8 O2) FORMUL 14 HOH *95(H2 O) SHEET 1 AA 2 GHP A 4 GHP A 5 0 SHEET 2 AA 2 DAL D 4 DAL D 5 -1 O DAL D 5 N GHP A 4 SHEET 1 BA 2 GHP B 4 GHP B 5 0 SHEET 2 BA 2 DAL E 4 DAL E 5 -1 O DAL E 5 N GHP B 4 LINK C MLU A 1 N OMZ A 2 1555 1555 1.35 LINK C OMZ A 2 N ASN A 3 1555 1555 1.32 LINK OH OMZ A 2 C3 GHP A 4 1555 1555 1.39 LINK C ASN A 3 N GHP A 4 1555 1555 1.34 LINK C GHP A 4 N GHP A 5 1555 1555 1.34 LINK C5 GHP A 4 OCZ OMY A 6 1555 1555 1.39 LINK C GHP A 5 N OMY A 6 1555 1555 1.35 LINK C5 GHP A 5 CG1 3FG A 7 1555 1555 1.49 LINK C OMY A 6 N 3FG A 7 1555 1555 1.35 LINK ODE OMY A 6 C1 DVC A 9 1555 1555 1.42 LINK C MLU B 1 N OMZ B 2 1555 1555 1.38 LINK C OMZ B 2 N ASN B 3 1555 1555 1.30 LINK OH OMZ B 2 C3 GHP B 4 1555 1555 1.39 LINK C ASN B 3 N GHP B 4 1555 1555 1.35 LINK C GHP B 4 N GHP B 5 1555 1555 1.34 LINK C5 GHP B 4 OCZ OMY B 6 1555 1555 1.40 LINK C GHP B 5 N OMY B 6 1555 1555 1.32 LINK C5 GHP B 5 CG1 3FG B 7 1555 1555 1.49 LINK C OMY B 6 N 3FG B 7 1555 1555 1.31 LINK ODE OMY B 6 C1 DVC B 9 1555 1555 1.42 LINK C MLU C 1 N OMZ C 2 1555 1555 1.38 LINK C OMZ C 2 N ASN C 3 1555 1555 1.31 LINK OH OMZ C 2 C3 GHP C 4 1555 1555 1.41 LINK C ASN C 3 N GHP C 4 1555 1555 1.34 LINK C GHP C 4 N GHP C 5 1555 1555 1.33 LINK C5 GHP C 4 OCZ OMY C 6 1555 1555 1.39 LINK C GHP C 5 N OMY C 6 1555 1555 1.33 LINK C5 GHP C 5 CG1 3FG C 7 1555 1555 1.50 LINK C OMY C 6 N 3FG C 7 1555 1555 1.33 LINK ODE OMY C 6 C1 DVC C 9 1555 1555 1.39 LINK CD FGA D 2 N LYS D 3 1555 1555 1.45 LINK C LYS D 3 N DAL D 4 1555 1555 1.31 LINK C DAL D 4 N DAL D 5 1555 1555 1.30 LINK C BDAL E 1 N FGA E 2 1555 1555 1.45 LINK C ADAL E 1 N FGA E 2 1555 1555 1.36 LINK CD FGA E 2 N LYS E 3 1555 1555 1.33 LINK C LYS E 3 N DAL E 4 1555 1555 1.32 LINK C DAL E 4 N DAL E 5 1555 1555 1.33 LINK CD FGA F 2 N LYS F 3 1555 1555 1.42 LINK C LYS F 3 N DAL F 4 1555 1555 1.33 LINK C DAL F 4 N DAL F 5 1555 1555 1.34 CISPEP 1 GHP A 5 OMY A 6 0 10.12 CISPEP 2 GHP B 5 OMY B 6 0 -0.30 CISPEP 3 GHP C 5 OMY C 6 0 5.84 CRYST1 48.290 48.290 39.300 90.00 90.00 120.00 P 32 2 1 18 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020708 0.011956 0.000000 0.00000 SCALE2 0.000000 0.023912 0.000000 0.00000 SCALE3 0.000000 0.000000 0.025445 0.00000 MTRIX1 1 -0.818060 -0.282480 -0.500970 69.43897 1 MTRIX2 1 0.274980 0.572940 -0.772090 18.29514 1 MTRIX3 1 0.505130 -0.769380 -0.391030 12.76565 1 MTRIX1 2 -0.784650 0.257220 0.564060 40.43910 1 MTRIX2 2 0.349730 -0.567600 0.745340 -24.31767 1 MTRIX3 2 0.511870 0.782100 0.355410 -7.14059 1 HETATM 1 N MLU A 1 37.001 11.985 28.408 1.00 14.60 N ANISOU 1 N MLU A 1 1808 1207 2530 -191 50 65 N HETATM 2 CN MLU A 1 37.979 12.806 29.046 1.00 19.84 C ANISOU 2 CN MLU A 1 2371 1499 3668 -198 -651 -575 C HETATM 3 CA MLU A 1 37.312 10.562 28.295 1.00 12.08 C ANISOU 3 CA MLU A 1 1487 1053 2050 -162 45 -42 C HETATM 4 C MLU A 1 37.526 10.030 29.728 1.00 11.67 C ANISOU 4 C MLU A 1 1359 1165 1908 -183 -55 -207 C HETATM 5 O MLU A 1 36.855 10.510 30.592 1.00 15.39 O ANISOU 5 O MLU A 1 2058 1562 2229 323 -42 -171 O HETATM 6 CB MLU A 1 36.169 9.760 27.683 1.00 11.84 C ANISOU 6 CB MLU A 1 1196 1316 1985 -9 -34 48 C HETATM 7 CG MLU A 1 35.733 10.133 26.264 1.00 12.07 C ANISOU 7 CG MLU A 1 1367 1353 1865 105 120 194 C HETATM 8 CD1 MLU A 1 36.867 10.070 25.304 1.00 17.04 C ANISOU 8 CD1 MLU A 1 1701 2345 2429 140 348 491 C HETATM 9 CD2 MLU A 1 34.589 9.244 25.882 1.00 13.32 C ANISOU 9 CD2 MLU A 1 1510 1557 1995 97 -103 46 C HETATM 10 N OMZ A 2 38.372 8.985 29.889 1.00 11.00 N ANISOU 10 N OMZ A 2 1128 1104 1948 -295 -271 -189 N HETATM 11 CA OMZ A 2 38.433 8.296 31.182 1.00 10.70 C ANISOU 11 CA OMZ A 2 1112 1176 1777 -193 -357 -431 C HETATM 12 C OMZ A 2 37.672 6.992 31.192 1.00 9.53 C ANISOU 12 C OMZ A 2 942 1171 1509 -156 -308 -260 C HETATM 13 O OMZ A 2 37.526 6.435 32.295 1.00 10.72 O ANISOU 13 O OMZ A 2 1296 1275 1503 -156 -504 -262 O HETATM 14 CB OMZ A 2 39.914 8.049 31.703 1.00 11.86 C ANISOU 14 CB OMZ A 2 1059 1245 2202 -274 -531 -325 C HETATM 15 OC OMZ A 2 40.583 9.329 31.648 1.00 15.62 O ANISOU 15 OC OMZ A 2 1288 1340 3306 -378 -806 -404 O HETATM 16 CG OMZ A 2 40.618 7.023 30.926 1.00 11.89 C ANISOU 16 CG OMZ A 2 933 1309 2278 -139 -593 -220 C HETATM 17 CD1 OMZ A 2 40.548 5.703 31.364 1.00 11.82 C ANISOU 17 CD1 OMZ A 2 1063 1298 2131 -141 -548 -325 C HETATM 18 CD2 OMZ A 2 41.240 7.310 29.718 1.00 12.52 C ANISOU 18 CD2 OMZ A 2 1047 1376 2332 -202 -500 -70 C HETATM 19 CE1 OMZ A 2 41.082 4.679 30.549 1.00 11.38 C ANISOU 19 CE1 OMZ A 2 1035 1118 2173 -28 -521 -265 C HETATM 20 CL OMZ A 2 41.036 3.092 31.042 1.00 15.14 CL ANISOU 20 CL OMZ A 2 1472 1647 2634 -151 -474 -267 CL HETATM 21 CE2 OMZ A 2 41.754 6.335 28.942 1.00 12.61 C ANISOU 21 CE2 OMZ A 2 943 1523 2324 -192 -279 -123 C HETATM 22 CZ OMZ A 2 41.592 4.999 29.340 1.00 11.97 C ANISOU 22 CZ OMZ A 2 850 1455 2243 -138 -483 -364 C HETATM 23 OH OMZ A 2 42.032 4.002 28.467 1.00 12.82 O ANISOU 23 OH OMZ A 2 841 1616 2413 -144 -357 -444 O